Sep 10, 2026 · 2h 51m
Biohacking experts debate peptide regulations and hormone optimization strategies
Best Peptides, Stem Cells, Testosterone & Exercise Hacks - Biohacking Roundtable - #1148
As advanced therapies go mainstream, patients must navigate the tension between cutting-edge longevity science, regulatory crackdowns, and foundational lifestyle habits.
- 1Microdosing GLP-1 receptor agonists shows promise for inflammation, but rapid use carries a major risk of muscle wasting.
- 2The FDA restriction on compounding peptides is sparking a major regulatory battle over medical freedom and patient access.
- 3Foundational health metrics like VO2 max and grip strength remain more critical for longevity than expensive experimental therapies.
Don't miss
Brigham Buhler details his experience lobbying in Washington D.C. to fight the FDA restrictions on compounding peptides.
The brief
Dr. Gabrielle Lyon, Ben Greenfield, and Brigham Buhler join host Chris Williamson for a roundtable on the frontier of longevity, hormone optimization, and the shifting regulatory landscape of wellness.
The panel debates the rise of GLP-1 receptor agonists, warning that rapid weight loss without proper protein intake risks muscle wasting, while also exploring how these drugs impact dopamine and mental health.
As the FDA restricts access to compounding peptides like BPC-157, the discussion turns to medical freedom and the lobbying efforts required to protect patient access to advanced therapies.
From experimental follistatin gene therapy and plasmapheresis to cost-free habits like resonance breathing, the guests contrast high-tech interventions with foundational metrics like grip strength and VO2 max.
Ben Greenfield
GLP-1 receptor agonist
Inflammation
HealthspanBooks & mentions
The Peter Attia Drive
For deep-dive scientific discussions on longevity, medicine, and healthspan.
Listen to the full episode and explore every guest, topic, and moment on PodLume.